**About PharmaCare**

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

### Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>boceprevir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Victrelis™</td>
</tr>
<tr>
<td>Dosage Form(s)</td>
<td>200 mg Capsule</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Merck Canada Inc.</td>
</tr>
</tbody>
</table>

#### Submission Review

<table>
<thead>
<tr>
<th>Use Reviewed</th>
<th>For treatment of chronic hepatitis C virus infection in patients co-infected with HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Drug Review (CDR)</td>
<td>CDR recommended boceprevir be listed for the treatment of chronic hepatitis C genotype 1 infection in patients with compensated liver disease, in combination with peginterferon alpha (PegIFNα)/ribavirin (RBV).</td>
</tr>
</tbody>
</table>

[http://www.cadth.ca/media/cdr/complete/cdr_complete_SF0312-Victrelis_RFA_June-14-13.pdf](http://www.cadth.ca/media/cdr/complete/cdr_complete_SF0312-Victrelis_RFA_June-14-13.pdf)

| Drug Benefit Council (DBC) | Boceprevir request for modification of criteria was not reviewed by the Drug Benefit Council |

#### Drug Coverage Decision

**LIMITED COVERAGE CRITERIA with modified criteria**


<table>
<thead>
<tr>
<th>Date</th>
<th>October 10, 2013</th>
</tr>
</thead>
</table>

**Reason(s)**

- At the time when boceprevir was initially reviewed for coverage, evidence was not available for the treatment of patients co-infected with hepatitis C virus (HCV) and HIV. As a result, patients with HCV and HIV were not eligible for PharmaCare coverage.
- The Limited Coverage criteria indicated that boceprevir in this patient will be reviewed as new information becomes available.
- Based on the recent review by the CDR, the Canadian Drug Expert Committee (CDEC) noted that the use of boceprevir in patients co-infected with HCV and HIV continues to be investigated and that boceprevir may provide clinical benefit in this patient population where there is an unmet therapeutic need. The treatment of patients co-infected with HCV and HIV should be under the direction of a physician experienced in managing such patients.
- As a result of this review, boceprevir coverage will be expanded to patients co-infected with HCV and HIV as a Limited Coverage benefit.

**Other Information**

None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council gives advice to the Ministry. The Council looks at:
- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:
- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug


To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit www.health.gov.bc.ca/pharmacare.

This document is intended for information only.
It does not take the place of advice from a physician or other qualified health care provider.